On April 1, 2026, Oncolytics Biotech Inc. (Nasdaq: ONCY) announced the successful completion of its redomestication from Alberta, Canada, to Nevada, USA. This strategic move, which was approved by shareholders at a special meeting on January 15, 2026, is expected to enhance the company's operational efficiency and streamline its regulatory framework. The transition involved a two-step process, first continuing the company’s existence from Alberta to British Columbia on March 17, 2026, followed by the final domestication to Nevada on March 31, 2026. The company will maintain its headquarters in San Diego, California, while retaining its Calgary office. The common stock of Oncolytics will continue to trade on The Nasdaq Stock Market under the ticker symbol 'ONCY'. Effective April 1, 2026, the CUSIP number for the common stock will be 68237V 103, and the ISIN will be US68237V1035. The leadership of Oncolytics expressed optimism about the benefits of Nevada's corporate legal environment, particularly for biotech companies. CEO Jared Kelly stated, 'We believe our new corporate structure will streamline our ability to execute on our goals.' This move is anticipated to improve access to U.S. capital markets and align the company’s corporate structure with its status as a U.S. domestic issuer. The company is focused on advancing its investigational immunotherapy, pelareorep, which has shown promise in various cancer studies. The completion of the domestication marks a significant milestone in Oncolytics' strategy to enhance shareholder value and operational capabilities.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.